Anselma Liturri

Dr. Anselma Liturri

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SFSilvana Filieri
Silvana Filieri
Morena MiciacciaMorena Miciaccia
Morena Miciaccia
DADomenico Armenise
Domenico Armenise
OBOlga Maria Baldelli
Olga Maria Baldelli
ALAnselma Liturri
Anselma Liturri
ASAntonio Scilimati
Antonio Scilimati
Background: The blood–brain barrier (BBB) plays an important role in regulating homeostasis of the central nervous system (CNS), and it is an obstacle for molecules with a molecular weight higher than 500 Da seeking to reach it, making many drugs ineffective simply because they cannot be delivered to where they are needed. As a result, crossing the BBB remains the rate-limiting factor in brain drug delivery during the treatment of brain diseases, specifically tumors such as diffuse intrinsic pontine glioma (DIPG), a highly aggressive pediatric tumor with onset in the pons Varolii, the middle portion of the three contiguous parts of the brainstem, located above the medulla and below the midbrain. Methods: Currently, radiotherapy (RT) relieves DIPG symptoms but chemotherapy drugs do not lead to significant results as they do not easily cross the BBB. Focused ultrasound (FUS) and microbubbles (MBs) can temporarily open the BBB, facilitating radiotherapy and the entry of drugs into the CNS. A patient-derived xenograft DIPG model exposed to high-intensity focalized ultrasound (HIFU) or low-intensity focalized ultrasound (LIFU) combined with MBs was treated with doxorubicin, panobinostat, olaparib, ONC201 (Dordaviprone®) and anti-PD1. Panobinostat has also been used in children with diffuse midline glioma, a broad class of brain tumors to which DIPG belongs. Results: Preliminary studies were performed using FUS to temporarily open the BBB and allow a milder use of radiotherapy and facilitate the passage of drugs through the BBB. The data collected show that after opening the BBB with FUS and MBs, drug delivery to the CNS significantly improved. Conclusions: FUS associated with MBs appears safe and feasible and represents a new strategy to increase the uptake of drugs in the CNS and therefore enhance their effectiveness. This review reports pre-clinical and clinical studies performed to demonstrate the usefulness of FUS in patients with DIPG treated with some chemotherapy. The papers reviewed were published in PubMed until the end of 2024 and were found using a combination of the following keywords: diffuse intrinsic pontine glioma (DIPG), DIPG H3K27-altered, blood–brain barrier and BBB, focused ultrasound (FUS) and radiotherapy (RT).

25 September 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DADomenico Armenise
Domenico Armenise
OBOlga Maria Baldelli
Olga Maria Baldelli
ALAnselma Liturri
Anselma Liturri
GCGianfranco Cavallaro
Gianfranco Cavallaro
CFCosimo Gianluca Fortuna
Cosimo Gianluca Fortuna
ASAntonio Scilimati
Antonio Scilimati
Background: The human mitochondrial ClpP is a serine protease located in the mitochondrial matrix responsible for degrading short lived regulatory proteins as well as misfolded or damaged proteins, thereby maintaining cellular homeostasis. Proteastasis dysregulation is linked to tumor progression. Methods: We conducted a literature review (2020–2025) using PubMed and Scopus, focusing on studies addressing ClpP structure, function, activity modulation, and cancer relevance. Keywords included “ClpP”, “ClpP activators”, “ClpP inhibitors”, and “mitochondrial protease”. Results: ClpP is upregulated in many tumors compared to normal tissues. Cancer cells depend on ClpP for mitochondrial proteostasis, metabolic adaptation, and survival. ClpP proteolytic activity modulation—via activators or inhibitors—disrupts these processes showing efficacy even in clinical setting. Conclusions: ClpP is emerging as a key player in cancer pathophysiology and holds potential as a therapeutic target. Its selective overexpression in tumors, along with its involvement in mitochondrial homeostasis, makes it a compelling candidate for precision oncology.

11 December 2025 in ACS Applied Materials & Interfaces
Verified
Journal Article
Open access
MOMónica Onrubia-Márquez
Mónica Onrubia-Márquez
FNFrancisco Navas
Francisco Navas
ESEsther M. Sánchez-Carnerero
Esther M. Sánchez-Carnerero
AMAntonio Martin
Antonio Martin
ALAnselma Liturri
Anselma Liturri
VMVictoria Morales
Victoria Morales
Neurodegenerative diseases (NDs) are progressive and fatal disorders that primarily affect the elderly and remain incurable. Characterized by irreversible neuronal loss, they leave patients increasingly dependent on caregivers. Despite diverse clinical presentations, NDs share common pathological features, such as protein aggregation, metal accumulation, oxidative stress, and chronic neuroinflammation. Despite numerous efforts, most therapeutic candidates fail due to poor efficacy, toxicity concerns, or limited blood-brain barrier (BBB) permeability, thereby highlighting the need for enhanced formulations. Nanomedicine offers a promising strategy to improve the therapeutic performance of existing compounds. This study presents a nanoformulation of the metal chelator deferoxamine (DFO) based on the drug-structure-directing agent (DSDA) concept, in which a hydrophobic chain is covalently linked to the DFO molecule to impart amphiphilic properties and acts as a template for the synthesis of a mesoporous silica nanoparticle (MSN). This approach allows for the one-pot fabrication of DFO-loaded MSNs (DFO@MSNs) with controlled sizes of below 20 nm without the need for surfactant removal. Compared to MCM-41-based systems, DFO@MSNs exhibited a higher drug loading capacity (10 mg of DFO/100 mg of MSNs) and a significantly more sustained release profile, minimizing premature leakage, with less than 20% of the cargo released over 24 h. Safety of DFO@MSN was assessed using BV-2 microglial and human neuroblastoma SH-SY5Y cell lines, and in vitro assays confirmed its enhanced iron-chelating capacity and effective inhibition of aluminum-induced amyloid aggregation. Furthermore, permeability studies using a Caco-2 in vitro BBB model revealed that a smaller particle size greatly enhances transport across the barrier. These results support DFO@MSNs as a promising multifunctional nanoplatform for targeted chelation therapy and neuroprotection in ND treatment.

5 March 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Maria Grazia PerroneMaria Grazia Perrone
Maria Grazia Perrone
SFSilvana Filieri
Silvana Filieri
Amalia AzzaritiAmalia Azzariti
Amalia Azzariti
DADomenico Armenise
Domenico Armenise
OBOlga Maria Baldelli
Olga Maria Baldelli
ASAntonio Scilimati
Antonio Scilimati
Background: Identification of targetable biomarkers to improve early disease detection and overall patient outcomes is becoming an urgent need in clinical oncology. Ovarian cancer (OC) has one of the highest mortality rates among gynecological cancers. It is asymptomatic and almost always diagnosed at an advanced stage (III or IV), leading to a 5-year survival rate of approximately 35%. Methods: Current therapeutic approaches for OC are very limited and mainly consist of cytoreductive surgery and cisplatin plus taxane-based chemotherapy. No gender and tumor specific biomarkers are known. Exosomes, lipid bilayer vesicles of endocytic origin secreted by most cell types, represent sources of information for their involvement in the onset and progression of many diseases. Hence, research on exosome contents as tools and targets in precise oncology therapy provides knowledge essential to improving diagnosis and prognosis of the disease. Results: This review attempts to give an overview of how exosomes are implicated in ovarian carcinoma pathogenesis to trigger further cancer exosome-based investigations aimed at developing ovarian cancer fine-tuning diagnostic methodologies. Conclusions: It is essential to investigate exosome-based cancer drugs to advance understanding, improve treatment plans, create personalized strategies, ensure safety, and speed up clinical translation to increase patients’ overall survival and quality of life. Papers published in PubMed and Web of Science databases in the last five years (2020–2024) were used as a bibliographic source.

20 January 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RSRoberta Solidoro
Roberta Solidoro
Morena MiciacciaMorena Miciaccia
Morena Miciaccia
DADomenico Armenise
Domenico Armenise
OBOlga Maria Baldelli
Olga Maria Baldelli
SFSavina Ferorelli
Savina Ferorelli
ASAntonio Scilimati
Antonio Scilimati

21 February 2025 in Catalysts
Verified
Journal Article
Open access
PDF file
Francesco MessaFrancesco Messa
Francesco Messa
DADomenico Armenise
Domenico Armenise
ALAnselma Liturri
Anselma Liturri
Maria Grazia PerroneMaria Grazia Perrone
Maria Grazia Perrone
Serena PerroneSerena Perrone
Serena Perrone
Antonio SalomoneAntonio Salomone
Antonio Salomone
This study outlines the sustainable synthesis of novel hydroxytyrosol (HT) and tyrosol (T) ester derivatives via a Pd-catalyzed alkoxycarbonylation of aromatic iodides. The high sustainability of the process is attributed to the use of (1) a solid carbon monoxide source, Mo(CO)6, in place of dangerous gaseous CO; (2) a biomass-derived organic solvent, CPME (cyclopentyl methyl ether); (3) naturally occurring hydroxylated compounds, such as HT and T, which could be derived from agricultural waste rather than produced from petroleum-based sources. The method enables the regioselective preparation of various HT and T esters in a short reaction time (4–8 h), under mild temperatures (80 °C), and with moderate-to-excellent yields (62–93%). Moreover, in vitro biological tests have demonstrated that, in addition to the well-known antioxidant properties typical of natural phenolic compounds such as HT and T, some of the newly synthesized derivatives have a safe profile and are effective inhibitors of the α-glucosidase with potential application in the management of hyperglycemia. This synthetic approach offers a promising strategy for exploring biologically relevant chemical space, bridging the gap between natural products and sustainable drug synthesis.